A smooth operator is our 'uncle'.
I believe NAM are researching prostate drugs, not really my sector but these stocks can be more volatile than the techies...well worth watching along with Cambridge antibody CAT.
failing to break 580 resistance level, NAM being falling for two days..today -30 to 525...even530 support level where it formed double bottom last week didn't help..
Although it said trading was in line with expectations, it also said the flotation of APBiotech, its joint venture with Pharmacia Corporation, would take place, subject to market conditions, after Nycomed's full-year results in February...that and ING Barings Charterhouse reiterating its "sell" recommendation on the stock caused NAM to fall 55p in two days...lowest since end of April...
"Nycomed is an exciting, professionally run company, promising us everything from diagnostic tests for Parkinson's disease to new ways of screening lungs. The shares are only likely to travel sideways over the next couple of months. Hold."